Piper Sandler Maintains Scholar Rock(SRRK.US) With Buy Rating
Why Scholar Rock Holding Stock Topped the Market Today
Piper Sandler Remains a Buy on Scholar Rock Holding (SRRK)
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Express News | Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Scholar Rock Holding Corporation's (NASDAQ:SRRK) Profit Outlook
Truist Financial Maintains Scholar Rock(SRRK.US) With Buy Rating, Announces Target Price $45
Insider Sale: Chief Commercial Officer of $SRRK Sells 5,000 Shares
Scholar Rock Application for Spinal Muscular Atrophy Treatment Gets FDA Approval
Scholar Rock Announces FDA Priority Review Designation For Apitegromab - Quick Facts
Scholar Rock Holding Corporation Says FDA Grants Priority Review For Biologics License Application And EMA Accepts Marketing Authorisation Application For Apitegromab As A Treatment For Spinal Muscular Atrophy
Express News | Scholar Rock Holding Corp - Plans U.S. Commercial Launch in 2025
Express News | Scholar Rock Holding Corp - FDA Pdufa Date for Apitegromab Set for September 22, 2025
Express News | FDA Grants Priority Review for Biologics License Application (Bla) and EMA Accepts Marketing Authorisation Application (Maa) for Apitegromab as a Treatment for Spinal Muscular Atrophy
Scholar Rock Holding Appoints Interim Financial Officer
Express News | Scholar Rock Holding Corp: Appoints Erin Moore as Interim Principal Financial Officer & Interim Principal Accounting Officer, Effective March 21, 2025
Truist Financial Maintains Scholar Rock(SRRK.US) With Buy Rating
TD Cowen Maintains Scholar Rock(SRRK.US) With Buy Rating
Scholar Rock Stock Jumps On Additional Data From Pivotal Trial Of Muscular Dystrophy Treatment
Express News | Scholar Rock Shares Are Trading Higher After the Company Announced Its Phase 3 SAPPHIRE Data Results